More recently, the clinical efficacy of anti-PD-1/PD-L1 antibodies and therapeutic strategies inhibiting the vascular endothelial growth factor (VEGF)/VEGF receptor axis has been evaluated in RCC patients. The gene discussed is CD274; the disease is renal cell carcinoma.